Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Latadin - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/Latadin

Approved

STANDARD

Latadin

Egyptian International Pharmaceutical Industries Co.🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: 7c3a9c25024c83bd
Company: Egyptian International Pharmaceutical Industries Co.
Type: Standard

Approval Details

Approval Id: 7c3a9c25024c83bd
Drug Approval Philippines Name: Latadin
Product Name: Latadin
Registration Number: DRP-8046-01
Brand Name: Latadin
Generic Name: Latanoprost
Dosage Form: Sterile Ophthalmic Solution (Eye Drops)
Dosage Strength: 50 mcg/mL (0.005% w/v)
Manufacturer: Egyptian International Pharmaceutical Industries Co.
Importer: Ambica International Corporation
Distributor: Medchoice Vision Care Inc.
Issuance Date: 24 October 2022
Expiry Date: 05 December 2028
Pharmacologic Category: Prostaglandin Analogue (Antiglaucoma)
Classification: Prescription Drug (RX)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

7c3a9c25024c83bd

Type

Standard

Back to Philippines FDA Approvals